Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma is an aggressive malignant lymphoma that constitutes approximately 30%-40% of all cases of non-Hodgkin lymphoma (NHL), making it the most common type of lymphoma. While once considered to be a single disease entity, many distinct clinical and morphological variants are now recognized.[1] Additionally, over recent years, gene expression profiling and other molecular high resolution technologies have revealed that DLBCL is genetically heterogeneous. According to gene expression profiling, most cases can be divided into one of two major molecular subtypes, according to their cell of origin (COO) - a germinal center B-cell (GCB) subtype or an activated B-cell (ABC) subtype.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2s2vjSg
via IFTTT